These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35137340)

  • 81. Evaluating the Presence of Cognitive Biases in Health Care Decision Making: A Survey of U.S. Formulary Decision Makers.
    Mezzio DJ; Nguyen VB; Kiselica A; O'Day K
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1173-1183. PubMed ID: 30362919
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation.
    Carlton J; Karnon J; Czoski-Murray C; Smith KJ; Marr J
    Health Technol Assess; 2008 Jun; 12(25):iii, xi-194. PubMed ID: 18513466
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
    Heather EM; Payne K; Harrison M; Symmons DP
    Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Health technology assessment in the cost-disutility plane.
    Eckermann S; Briggs A; Willan AR
    Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reduced uncertainty as a diagnostic benefit: an initial assessment of somatostatic receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumours.
    Woodward RS; Schnitzler MA; Kvols LK
    Health Econ; 1998 Mar; 7(2):149-60. PubMed ID: 9565171
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Treatment decisions under ambiguity.
    Berger L; Bleichrodt H; Eeckhoudt L
    J Health Econ; 2013 May; 32(3):559-69. PubMed ID: 23537710
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.
    Mugford M; Hutton G; Fox-Rushby J
    Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724
    [TBL] [Abstract][Full Text] [Related]  

  • 89. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia.
    Lu L; Peters J; Roome C; Stein K
    Int J Technol Assess Health Care; 2012 Jul; 28(3):241-8. PubMed ID: 22980700
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.
    Al MJ; Feenstra TL; Hout BA
    Health Econ; 2005 Jul; 14(7):655-67. PubMed ID: 15678518
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom.
    Vaidya A; Vaidya P; Both B; Brew-Graves C; Bulsara M; Vaidya JS
    BMJ Open; 2017 Aug; 7(8):e014944. PubMed ID: 28819067
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cost data in implementation science: categories and approaches to costing.
    Gold HT; McDermott C; Hoomans T; Wagner TH
    Implement Sci; 2022 Jan; 17(1):11. PubMed ID: 35090508
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Allocating health care resources when people are risk averse with respect to life time.
    Hoel M
    Health Econ; 2003 Jul; 12(7):601-8. PubMed ID: 12825211
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A cost-effectiveness analysis of a program to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba.
    Watkins DA; Mvundura M; Nordet P; Mayosi BM
    PLoS One; 2015; 10(3):e0121363. PubMed ID: 25768008
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost-effectiveness analysis with risk aversion.
    Zivin JG
    Health Econ; 2001 Sep; 10(6):499-508. PubMed ID: 11550291
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A framework for addressing structural uncertainty in decision models.
    Jackson CH; Bojke L; Thompson SG; Claxton K; Sharples LD
    Med Decis Making; 2011; 31(4):662-74. PubMed ID: 21602487
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Expected utility of voluntary vaccination in the middle of an emergent Bluetongue virus serotype 8 epidemic: a decision analysis parameterized for Dutch circumstances.
    Sok J; Hogeveen H; Elbers AR; Velthuis AG; Oude Lansink AG
    Prev Vet Med; 2014 Aug; 115(3-4):75-87. PubMed ID: 24768508
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A Framework for the Fair Pricing of Medicines.
    Paulden M
    Pharmacoeconomics; 2024 Feb; 42(2):145-164. PubMed ID: 38066357
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.